R J Kreitman

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity
    Sookhee Bang
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, 37 Convent Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 11:1545-50. 2005
  2. doi request reprint Hairy cell leukemia-new genes, new targets
    Robert J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Hematol Malig Rep 8:184-95. 2013
  3. pmc Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia
    Robert J Kreitman
    National Cancer Institute, National Institutesof Health, Bethesda, USA
    J Clin Oncol 30:1822-8. 2012
  4. ncbi request reprint Recombinant fusion toxins for cancer treatment
    Robert J Kreitman
    Clinical Immunotherapy Section, Laboratory of Molecular Biology, Division of Cancer Biology, National Cancer Institute National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
    Expert Opin Biol Ther 2:785-91. 2002
  5. ncbi request reprint Immunotoxins in the treatment of hematologic malignancies
    Robert J Kreitman
    Clinical Immunotherapy Section, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
    Curr Drug Targets 7:1301-11. 2006
  6. pmc Immunotoxins for targeted cancer therapy
    Robert J Kreitman
    Clinical Immunotherapy Section, Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
    AAPS J 8:E532-51. 2006
  7. ncbi request reprint BL22 and lymphoid malignancies
    Robert J Kreitman
    Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
    Best Pract Res Clin Haematol 19:685-99. 2006
  8. ncbi request reprint Immunotoxins in the treatment of refractory hairy cell leukemia
    Robert J Kreitman
    Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
    Hematol Oncol Clin North Am 20:1137-51, viii. 2006
  9. ncbi request reprint Recombinant toxins for the treatment of cancer
    Robert J Kreitman
    Division of Cancer Biology, National Institutes of Health, 9000 Rockville, Bethesda, MD 20892, USA
    Curr Opin Mol Ther 5:44-51. 2003
  10. ncbi request reprint Immunobiological treatments of hairy-cell leukaemia
    Robert J Kreitman
    Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5106, Bethesda, MD 20892 4255, USA
    Best Pract Res Clin Haematol 16:117-33. 2003

Collaborators

Detail Information

Publications69

  1. ncbi request reprint HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity
    Sookhee Bang
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, 37 Convent Drive, Bethesda, MD 20892, USA
    Clin Cancer Res 11:1545-50. 2005
    ..HA22 is a mutant of BL22 with mutations in heavy-chain CDR3 resulting in increased cytotoxic activity. Our goal was to improve the activity of HA22...
  2. doi request reprint Hairy cell leukemia-new genes, new targets
    Robert J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Curr Hematol Malig Rep 8:184-95. 2013
    ..One additional partial and one additional complete remission were subsequently reported...
  3. pmc Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia
    Robert J Kreitman
    National Cancer Institute, National Institutesof Health, Bethesda, USA
    J Clin Oncol 30:1822-8. 2012
    ..To conduct a phase I dose-escalation trial assessing safety and response of recombinant immunotoxin moxetumomab pasudotox (CAT-8015, HA22) in chemotherapy-resistant hairy cell leukemia (HCL)...
  4. ncbi request reprint Recombinant fusion toxins for cancer treatment
    Robert J Kreitman
    Clinical Immunotherapy Section, Laboratory of Molecular Biology, Division of Cancer Biology, National Cancer Institute National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
    Expert Opin Biol Ther 2:785-91. 2002
  5. ncbi request reprint Immunotoxins in the treatment of hematologic malignancies
    Robert J Kreitman
    Clinical Immunotherapy Section, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
    Curr Drug Targets 7:1301-11. 2006
    ..Several other recombinant immunotoxins are undergoing preclinical development for other target antigens expressed on hematologic malignancies...
  6. pmc Immunotoxins for targeted cancer therapy
    Robert J Kreitman
    Clinical Immunotherapy Section, Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
    AAPS J 8:E532-51. 2006
    ..Refinement of existing immunotoxins and development of new immunotoxins are underway to improve the treatment of cancer...
  7. ncbi request reprint BL22 and lymphoid malignancies
    Robert J Kreitman
    Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
    Best Pract Res Clin Haematol 19:685-99. 2006
    ..Already under way are a phase-II trial in HCL and phase-I trials in chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL) administering BL22 in a modified protocol in an effort to prevent HUS...
  8. ncbi request reprint Immunotoxins in the treatment of refractory hairy cell leukemia
    Robert J Kreitman
    Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
    Hematol Oncol Clin North Am 20:1137-51, viii. 2006
    ..Both agents, termed LMB-2 and BL22, respectively, have been tested in patients who have HCL after failure of purine analogs and other therapies; major responses have been achieved in most patients...
  9. ncbi request reprint Recombinant toxins for the treatment of cancer
    Robert J Kreitman
    Division of Cancer Biology, National Institutes of Health, 9000 Rockville, Bethesda, MD 20892, USA
    Curr Opin Mol Ther 5:44-51. 2003
    ..The number of approved recombinant toxins for the treatment of cancer is expected to increase in the coming years...
  10. ncbi request reprint Immunobiological treatments of hairy-cell leukaemia
    Robert J Kreitman
    Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5106, Bethesda, MD 20892 4255, USA
    Best Pract Res Clin Haematol 16:117-33. 2003
    ..The unlabelled mAb rituximab has also been reported to induce responses in the majority of HCL patients treated, and several CRs have been observed...
  11. ncbi request reprint Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies
    Robert J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bldg 5124b, 9000 Rockville Pike, Bethesda, MD 20892, USA
    J Clin Oncol 23:6719-29. 2005
    ..To conduct a phase I trial of recombinant immunotoxin BL22, an anti-CD22 Fv fragment fused to truncated Pseudomonas exotoxin...
  12. ncbi request reprint Confirmation and prevention of targeted toxicity by a recombinant fusion toxin
    Robert J Kreitman
    Clinical Immunotherapy Section, Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4255, USA
    Mol Cancer Ther 3:1691-2. 2004
  13. pmc Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies
    Robert J Kreitman
    Clinical Immunotherapy Section, Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    BioDrugs 23:1-13. 2009
    ..The most successful application of recombinant immunotoxins today is in hairy cell leukemia, where BL22 has induced complete remissions in most patients who were previously treated with optimal chemotherapy...
  14. pmc Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia
    Robert J Kreitman
    Laboratory of Molecular Biology, Laboratory of Clinical Pathology, and Medicine Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    J Clin Oncol 27:2983-90. 2009
    ..To conduct a phase II trial in chemoresistant hairy cell leukemia (HCL) with BL22, a recombinant anti-CD22 immunotoxin which showed phase I activity in HCL...
  15. ncbi request reprint Immunotoxins in cancer therapy
    R J Kreitman
    Laboratory of Molecular Biology, Division of Cancer Biology, National Cancer Institute, National Institutes of Health, 37 4B27, 9000 Rockville Pike, 4255 Bethesda, MD 20892, USA
    Curr Opin Immunol 11:570-8. 1999
    ..Efforts are underway to obviate impediments to clinical efficacy, including immunogenicity and toxicity to normal tissues. Immunotoxins are now being developed to new antigens for the treatment of cancer...
  16. ncbi request reprint Immunotoxins
    R J Kreitman
    Laboratory of Molecular Biology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, 37 4B27, 37 Convent Drive Msc 4255 Bethesda, MD 20892, USA
    Expert Opin Pharmacother 1:1117-29. 2000
    ..Some of these molecules may enter clinical practice in the future as targeted therapy, which is a modality distinct from those of chemotherapy, surgery and radiation therapy...
  17. pmc Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox
    Robert J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Clin Cancer Res 17:6398-405. 2011
    ..Moreover, protein engineering is being used to increase its activity, decrease nonspecific side effects, and remove B-cell epitopes...
  18. doi request reprint Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia
    Robert J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Leuk Lymphoma 52:82-6. 2011
    ..In separate randomized trials, rituximab is undergoing phase II testing with cladribine for early HCL and with bendamustine or pentostatin for multiply relapsed HCL...
  19. ncbi request reprint Recombinant immunotoxins for the treatment of haematological malignancies
    Robert J Kreitman
    Clinical Immunotherapy Section, Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Building 37, Room 5124b, Bethesda, MD 20892 4255, USA
    Expert Opin Biol Ther 4:1115-28. 2004
    ..One of these molecules, BL22, targets CD22 on hairy-cell leukaemia and has enabled patients to achieve complete remissions despite previous treatment and resistance to chemotherapy...
  20. ncbi request reprint Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia
    R J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, Bethesda, MD 20892, USA
    N Engl J Med 345:241-7. 2001
    ..We tested the safety and efficacy of an immunotoxin directed against a surface antigen that is strongly expressed by leukemic hairy cells...
  21. ncbi request reprint Chimeric fusion proteins--Pseudomonas exotoxin-based
    R J Kreitman
    National Cancer Institute, NIH, Clinical Immunotherapy Section, Laboratory of Molecular Biology, Division of Cancer Biology, 9000 Rockville Pike, Building 37, Room 4B 27, Bethesda, MD 20892 4255, USA
    Curr Opin Investig Drugs 2:1282-93. 2001
    ..This review will focus on several agents containing truncated Pseudomonas exotoxin, which are undergoing preclinical and clinical development...
  22. pmc Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P
    Robert J Kreitman
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 15:5274-9. 2009
    ..To conduct a phase I trial of recombinant immunotoxin SS1P given by continuous infusion in chemoresistant solid tumors expressing mesothelin...
  23. doi request reprint Approach to the patient after relapse of hairy cell leukemia
    Robert J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Leuk Lymphoma 50:32-7. 2009
    ..An improved high-affinity version of BL22, termed HA22, is currently undergoing phase I testing...
  24. ncbi request reprint Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies
    Robert J Kreitman
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 37 5124b, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Curr Pharm Des 15:2652-64. 2009
    ..HA22, an improved version of BL22 with higher affinity to CD22, is now undergoing phase I testing in HCL, CLL, non-Hodgkin's lymphoma, and pediatric acute lymphoblastic leukemia...
  25. ncbi request reprint Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma
    R K Puri
    Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, NIH, Bethesda, Maryland 20892, USA
    Cancer Res 56:5631-7. 1996
    ..We conclude that by localized administration, nontoxic levels of IL4(38-37)-PE38KDEL can be achieved, which may have significant cytotoxic activity against malignant astrocytoma...
  26. ncbi request reprint Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity
    M Onda
    Laboratory of Molecular Biology, Division of Basic Sciences, National Cancer Institute, NIH, Bethesda, Maryland 20892-4255, USA
    Cancer Res 61:5070-7. 2001
    ..Therefore, lowering the pI of the Fv may be a general approach to diminish the nonspecific toxicity of recombinant immunotoxins and other Fv fusion proteins without losing antitumor activity...
  27. ncbi request reprint Isolation of new anti-CD30 scFvs from DNA-immunized mice by phage display and biologic activity of recombinant immunotoxins produced by fusion with truncated pseudomonas exotoxin
    H Rozemuller
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Int J Cancer 92:861-70. 2001
    ..Our data show that DNA immunization and antibody phage display may be useful in producing new rITs against hematologic malignancies. Published 2001 Wiley-Liss, Inc...
  28. pmc Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity
    Y Tsutsumi
    Laboratory of Molecular Biology, Division of Basic Science, National Cancer Institute, National Institutes of Health, Building 37, Room 4E16, 37 Convent Drive MSC 4255, Bethesda, MD 20892 4255, USA
    Proc Natl Acad Sci U S A 97:8548-53. 2000
    ..This was accompanied by a substantial decrease in animal toxicity and immunogenicity. Site-specific PEGylation of recombinant immunotoxins may increase their therapeutic potency in humans...
  29. ncbi request reprint Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments
    Satoshi Nagata
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 8:2345-55. 2002
    ....
  30. ncbi request reprint Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients
    Masanori Onda
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
    J Immunol 177:8822-34. 2006
    ..Our results indicate that a relatively small number of discrete immunogenic sites are associated with PE38, most of which can be eliminated by point mutations...
  31. pmc A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
    John E Weldon
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892 4264, USA
    Blood 113:3792-800. 2009
    ..We conclude that HA22-LR advances the therapeutic efficacy of HA22 by using an approach that may be applicable to other PE-based immunotoxins...
  32. ncbi request reprint Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy
    Evgeny Arons
    Laboratories of Molecular Biology and Pathology, and Biostatistics and Data Management Section, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Cancer Immunol Immunother 55:1100-10. 2006
    ....
  33. ncbi request reprint Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies
    Tomoko Ise
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 11:87-96. 2005
    ..To study the expression of the IRTA2 gene product, we produced monoclonal antibodies (MAbs) specific to IRTA2...
  34. pmc SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice
    C Kimchi-Sarfaty
    Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4256, USA
    Cancer Gene Ther 13:648-57. 2006
    ..These results indicate that SV40 in vitro packaging is an effective system for cancer gene delivery using two different routes of injection and in combination with chemotherapy...
  35. pmc IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein
    B H Joshi
    Laboratory of Molecular Tumour Biology, Division of Cellular and Gene Therapies, Center for Biologics, Evaluation and Research, Food and Drug Administration, NIH Building 29B, Room 2NN10, 29 Lincoln Dr, Bethesda, Maryland, MD 20892, USA
    Br J Cancer 86:285-91. 2002
    ..Further studies are warranted to investigate interleukin-4 receptor expression in primary medulloblastoma tumours and sensitivity to cpIL-4PE in vitro and in vivo...
  36. ncbi request reprint Expression and targeting of interleukin-4 receptor for primary and advanced ovarian cancer therapy
    Mitomu Kioi
    Laboratory of Molecular Tumor Biology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA
    Cancer Res 65:8388-96. 2005
    ..These results indicate that IL-4R-targeted cytotoxin may be a useful agent for the management of patients with ovarian cancer, and further studies need to be done to evaluate its safety, tolerability, and efficacy...
  37. ncbi request reprint In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin
    Mitchell Ho
    Laboratory of Molecular Biology, Center for Cancer Research, NCI, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Biol Chem 280:607-17. 2005
    ..Our results demonstrate that germline hot spots but not non-germline hot spots are effective for in vitro antibody affinity maturation...
  38. pmc Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2
    Peter Attia
    Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunother 29:208-14. 2006
    ..The short in vivo half-life of LMB-2 makes it an attractive candidate for reducing human T(reg) cells in vivo before the administration of cancer vaccine or cell transfer immunotherapy approaches...
  39. ncbi request reprint Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma
    T Ise
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Leukemia 21:169-74. 2007
    ..Because CD307 is present on malignant cells from patients with MM, CLL and MCL, CD307 may be a useful therapeutic target for the treatment of these diseases...
  40. pmc Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo
    Daniel J Powell
    Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Immunol 179:4919-28. 2007
    ....
  41. ncbi request reprint Immunotoxin treatment of cancer
    Ira Pastan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Annu Rev Med 58:221-37. 2007
    ..Strategies to overcome these limitations are being pursued...
  42. ncbi request reprint Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
    Raffit Hassan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute and Clinical Center, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 13:5144-9. 2007
    ..To determine the toxicities, maximum tolerated dose (MTD) and pharmacokinetics of the recombinant immunotoxin SS1P (anti-mesothelin dsFv-PE38) in patients with mesothelin-expressing cancers...
  43. ncbi request reprint Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice
    David Filpula
    Enzon Pharmaceuticals, Incorporated, 20 Kingsbridge Road, Piscataway, New Jersey 08854, and Laboratory of Molecular Biology, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Bioconjug Chem 18:773-84. 2007
    ..Since the bioconjugates can also exhibit the attributes of passive targeting via enhanced permeability and retention, this is the first demonstration of a pivotal role of active targeting for immunotoxin bioconjugate efficacy...
  44. ncbi request reprint New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA
    Masanori Onda
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 11:5840-6. 2005
    ..We have produced novel MAbs to mesothelin to help study mesothelin function and to develop improved diagnosis and immunotherapy of mesothelin-expressing tumors...
  45. ncbi request reprint Immunotoxins in cancer therapy
    Ira Pastan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4264, USA
    Curr Opin Investig Drugs 3:1089-91. 2002
    ..Unfortunately, most antibodies do not kill cancer cells unless they are armed with a cytotoxic agent, such as a radioisotope, a cytotoxic drug, or a protein toxin. Each of these have advantages and disadvantages...
  46. pmc Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial
    Alan S Wayne
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 1104, USA
    Clin Cancer Res 16:1894-903. 2010
    ..We conducted the first preclinical and phase I clinical studies of BL22 in that setting...
  47. ncbi request reprint Immunotoxin therapy of cancer
    Ira Pastan
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institues of Health, 37 Convent Drive, Bethesda, MD 20892 4264, USA
    Nat Rev Cancer 6:559-65. 2006
    ..Results from clinical trials indicate that recombinant immunotoxins and similar agents that are designed to combine antibody selectivity with toxin cell-killing potency will be useful additions to cancer therapy...
  48. ncbi request reprint Localization of mesothelin in epithelial ovarian cancer
    Raffit Hassan
    Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892 4264, USA
    Appl Immunohistochem Mol Morphol 13:243-7. 2005
    ..Patients whose tumors express mesothelin could be eligible for participation in clinical trials of novel agents targeting mesothelin...
  49. ncbi request reprint Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display
    Giuliana Salvatore
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4264, USA
    Clin Cancer Res 8:995-1002. 2002
    ..The THW mutant had a 5- to 10-fold increase in activity on various CD22-positive cell lines and was up to 50 times more cytotoxic to cells from patients with chronic lymphocytic leukemia and hairy-cell leukemia...
  50. ncbi request reprint Toxin-labeled monoclonal antibodies
    R J Kreitman
    Laboratory of Molecular Biology, Division of Cancer Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Curr Pharm Biotechnol 2:313-25. 2001
    ..New recombinant immunotoxins are currently being engineered and developed to target other hematologic and solid tumor antigens...
  51. ncbi request reprint Immunoglobulin light chain repertoire in hairy cell leukemia
    Evgeny Arons
    Laboratories of Molecular Biology and Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4255, USA
    Leuk Res 31:1231-6. 2007
    ..In HCL, we confirm the lack of kappa predominance observed in normal lymphocytes and in chronic lymphocytic leukemia, and note over-representation of several light chain genes...
  52. pmc VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy
    Evgeny Arons
    Laboratories of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Blood 114:4687-95. 2009
    ..Response to initial single-agent cladribine therapy is suboptimal; these patients should be considered for alternative approaches, including antibody-related therapy...
  53. pmc Soluble CD22 as a tumor marker for hairy cell leukemia
    Kakushi Matsushita
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20854 4255, USA
    Blood 112:2272-7. 2008
    ..Trials are listed on www.cancer.gov as NCT00002765, NCT00021983, NCT00074048, NCT00085085, NCT00337311, and NCT00462189...
  54. ncbi request reprint Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction
    Evgeny Arons
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20892 4255, USA
    Clin Cancer Res 12:2804-11. 2006
    ..Thus, patient-specific RQ-PCR is the most sensitive test for MRD in HCL patients and could be used to determine maximal response in patients obtaining multiple cycles of nonmyelotoxic biological treatment for this disease...
  55. pmc PRAME expression in hairy cell leukemia
    Evgeny Arons
    Laboratories of Molecular Biology and Clinical Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892 4255, United States
    Leuk Res 32:1400-6. 2008
    ..We conclude that HCL and CLL differ in PRAME overexpression, and that basal normal expression of PRAME may limit its usefulness for following patients with minimal residual CLL or HCL...
  56. ncbi request reprint Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene
    Justin E Sausville
    Laboratory of Pathology, Bldg 10, Room 2N 108, Mail Stop 1500, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Am J Clin Pathol 119:213-7. 2003
    ..FC was adequate in 86 cases (100%), while cpPCR was adequate in 74 cases (86%). FC is superior to cpPCR for detecting minimal residual HCL. It is more sensitive and more specific and permits quantitation of tumor cell number...
  57. ncbi request reprint Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera
    Tomoko Ise
    Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, 37 Convent Drive, Bethesda, MD 20892, USA
    Clin Chem Lab Med 44:594-602. 2006
    ..The membrane form is highly expressed on the surface of hairy cell leukemia (HCL) cells from patients. This study aimed to develop immunoassays for soluble IRTA2/FcRH5 proteins in human serum...
  58. ncbi request reprint Somatic hypermutation and VH gene usage in hairy cell leukaemia
    Evgeny Arons
    Clinical Immunotherapy Section, Laboratory of Molecular Biology, Centers for Cancer Research, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Br J Haematol 133:504-12. 2006
    ....
  59. ncbi request reprint Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia
    Arthur E Frankel
    Wake Forest University Baptist Medical Center, Winston Salem, North Carolina 27157, USA
    Clin Cancer Res 8:1004-13. 2002
    ..We tested the safety and efficacy of a diphtheria fusion protein [diphtheria toxin (DT)388 granulocyte-macrophage colony-stimulating factor (GMCSF)] directed against the GMCSF receptor that is strongly expressed by leukemic blasts...
  60. ncbi request reprint Sensitization of B-cell chronic lymphocytic leukemia cells to recombinant immunotoxin by immunostimulatory phosphorothioate oligodeoxynucleotides
    Thomas Decker
    3rd Department of Medicine, Technical University of Munich, Munich, Germany
    Blood 99:1320-6. 2002
    ..In summary, immunostimulatory CpG-ODNs efficiently sensitize B-CLL cells to a recombinant immunotoxin by modulation of its target. This new treatment strategy deserves further attention...
  61. ncbi request reprint Augmentation of the activity of an immunotoxin, anti-Tac(Fv)-PE40KDEL, in T cell lines infected with human T cell leukemia virus type-I
    Nobuhito Ohno
    Department of Cancer Chemotherapy, Institute for Cancer Research, Kagoshima University, Japan
    Leuk Lymphoma 43:885-8. 2002
    ..CsA was the most potent agent in both the cell lines. Augmentation of the cytotoxic effect of the immunotoxin by these agents, especially CsA, may be useful in the immunotoxin therapy of ATL...
  62. ncbi request reprint Expression and purification of the recombinant diphtheria fusion toxin DT388IL3 for phase I clinical trials
    Jeffrey O Urieto
    Department of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Protein Expr Purif 33:123-33. 2004
    ..The synthesis of this protein drug should be useful for production for clinical phase I/II clinical trials and may be suitable for other diphtheria fusion toxins indicated for clinical development...
  63. ncbi request reprint Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts
    Bryce D Beseth
    Section of General Thoracic Surgery, University of California, Los Angeles, California 90095 1741, USA
    Ann Thorac Surg 78:436-43; discussion 436-43. 2004
    ..Malignant pleural mesothelioma (MPM) is an uncommon but highly fatal neoplasm for which only limited treatment is available...
  64. ncbi request reprint Immunotoxin therapy of hematologic malignancies
    Arthur E Frankel
    Wake Forest University School of Medicine, Winston Salem, NC, USA
    Semin Oncol 30:545-57. 2003
    ..Over the next several decades, a growing number of these agents should reach the clinic...
  65. ncbi request reprint Multidrug-resistant tumor cells remain sensitive to a recombinant interleukin-4-Pseudomonas exotoxin, except when overexpressing the multidrug resistance protein MRP1
    Mariska C de Jong
    Department of Pathology, VU University Medical Center, 1081 HV Amsterdam, The Netherlands
    Clin Cancer Res 9:5009-17. 2003
    ..Still, the results of this study demonstrate that IL-4 toxin effectively kills most MDR tumor cells and, therefore, represents a promising anticancer drug...
  66. doi request reprint Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia
    Ejaz Ahmad
    Good Samaritan Hospital, Dayton, Ohio, USA
    Cytometry B Clin Cytom 74:221-6. 2008
    ..To date no study has been conducted to evaluate and compare patterns of cell surface antigen expression in familial CLL and sporadic CLL...
  67. ncbi request reprint Taming ricin toxin
    Robert J Kreitman
    Nat Biotechnol 21:372-4. 2003
  68. ncbi request reprint CLL immunotoxins
    Arthur E Frankel
    Leuk Res 29:985-6. 2005
    ..A fraction of patients (19%) had CLL cells that were extremely sensitive to the immunotoxin. This novel agent may provide an important new therapeutic for use in the treatment of CLL...
  69. ncbi request reprint Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins
    Thomas Decker
    III Medizinische Klinik, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Blood 103:2718-26. 2004
    ..HA22 was more active than BL22. In conclusion, these immunotoxins induce caspase-mediated apoptosis involving mitochondrial damage. Combination with chemotherapy is expected to improve the efficacy of immunotoxin treatment...